TEARLAB CORPORATION (NASDAQ:TEAR) Files An 8-K Termination of a Material Definitive Agreement

TEARLAB CORPORATION (NASDAQ:TEAR) Files An 8-K Termination of a Material Definitive Agreement

Story continues below

Item 1.02 Termination of Material Definitive Agreement

On June 23, 2017, TearLab Corporation (the Company, we, or us)
entered into a mutual termination of the Amended and Restated
Cooperative Marketing Agreement with PRN Physician Recommended
Nutriceuticals LLC (PRN) to which the Company and PRN were
jointly promoting PRNs proprietary omega-3 formulations,
including Dry Eye Omega Benefits. The termination is effective
immediately, and all amounts due to the Company will be paid by
June 30, 2017.

Item 5.07 Submission of Matters to a Vote of Security

We held our 2017 annual meeting of stockholders on June 23, 2017
(the Annual Meeting). Of the 5,735,732 shares of our common stock
outstanding as the record date of April 28, 2017, 4,176,304
shares were represented at the Annual Meeting, either in person
or by proxy, constituting approximately 72.81% of the outstanding
shares of common stock. The matters voted on at the Annual
Meeting and the votes cast with respect to each such matter are
set forth below:

1. Election of Directors. Each of the following
nominees was elected to serve as a director, to hold office
until our 2018 annual meeting of stockholders and until his
or her respective successor has been duly elected and
qualified based on the following results of voting:
Nominee Votes For Votes Withheld Broker Non-Votes
Elias Vamvakas 1,734,819 277,701 2,163,784
Joseph Jensen 1,734,882 277,638 2,163,784
Anthony E. Altig 1,734,882 277,638 2,163,784
Thomas N. Davidson, Jr. 1,734,482 278,038 2,163,784
Adrienne L. Graves 1,734,607 277,913 2,163,784
Paul M. Karpecki 1,734,882 277,638 2,163,784
Richard L. Lindstrom 1,734,450 278,070 2,163,784
Donald E. Rindell 1,734,282 278,238 2,163,784
Brock J. Wright 1,734,450 278,070 2,163,784
2. Approval of Amendment and Restatement of 2002 Stock
Incentive Plan.
The amendment and restatement of our
2002 Stock Incentive Plan to increase the number of shares
reserved for issuance thereunder by 350,000 shares was
approved based on the following results of voting:
For Against Abstentions Broker Non-Votes
1,276,354 730,188 5,978 2,163,784
3. Ratification of Appointment of Independent Registered
Public Accounting Firm.
The appointment of Mayer
Hoffman McCann P.C. as our independent registered public
accounting firm for the fiscal year ending December 31, 2017
was ratified based on the following results of voting:
For Against Abstentions
4,108,689 17,595 50,020
4. Advisory Vote on Approval of Executive
On an advisory (non-binding) basis,
the stockholders approved the compensation of our named
executive officers for the year ended December 31, 2016 as
disclosed in our proxy statement:
For Against Abstentions Broker Non-Votes
1,709,347 299,465 3,708 2,163,784


TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

An ad to help with our costs